Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Durolane SJ is a **single-injection preparation of stabilized, non-animal-derived sodium hyaluronate** (a form of hyaluronic acid) indicated for the symptomatic treatment of mild to moderate **osteoarthritis pain affecting small joints**, such as the ankle, elbow, wrist, fingers, and toes. The product acts as a lubricant and shock absorber within the joint, replenishing natural hyaluronic acid and restoring the viscoelastic properties of synovial fluid lost in osteoarthritis. Its active ingredient is synthesized using proprietary NASHA technology and delivered as a clear, transparent, highly purified gel. The typical duration of effect for pain relief is up to six months, with some benefit observed as long as nine months in a subset of patients[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on durolane sj.